Ilika achieves pivotal breakthrough in Goliath battery programme

Ilika PLC (AIM:IKA, OTCQX:ILIKF) has achieved a significant milestone by commissioning its automated 1.5MWh Goliath solid-state battery pilot line, enabling consistent, high-yield cell production for customer validation and accelerating the commercialization of its large-format battery technology, with 10Ah and 50Ah prototypes slated for delivery. This development, supported by the PRIMED program with partners like Jaguar Land Rover, is expected to drive further traction in the automotive sector, as evidenced by the company's first Goliath revenue despite an overall sales decline in 2025. Concurrently, Ilika is progressing its Stereax batteries for medtech, anticipating commercial sales later this year following successful manufacturing equipment commissioning and a ten-year licensing agreement with Cirtec Medical.

Analysis

Ilika PLC (AIM:IKA, OTCQX:ILIKF) has achieved a significant operational milestone by commissioning its automated 1.5MWh Goliath solid-state battery (SSB) pilot line, now fully operational for consistent, high-yield cell production. This development is crucial for accelerating the commercialization of its large-format battery technology, with 10Ah P1.5 prototypes due from December and 50Ah P2 prototypes to follow. The upgraded automation supports the large volumes required for critical automotive and industrial testing, underscoring the company's progress towards market readiness.

The company's PRIMED program, a collaboration with Jaguar Land Rover and Oxford University, further targets industrial-scale prototyping of 50Ah A-Sample batteries, indicating strong industry engagement. Despite a reported decline in full-year sales to £1.1 million in 2025 from £2.1 million in 2024, Ilika secured its first Goliath-related revenue of £74,000 from a top-tier car parts supplier, signaling initial commercial traction. Analysts anticipate 2026 to be a pivotal year for Goliath's market penetration.

Concurrently, Ilika is advancing its Stereax battery technology for medical devices, having successfully commissioned manufacturing equipment at Cirtec Medical's facility in the US. This partnership, a ten-year licensing agreement, positions Stereax for commercial sales later this year, leveraging its miniaturization and high energy density for active implantable devices. This dual-track development in both large-format and specialized medical batteries highlights a diversified growth strategy.

Key Decisions for Investors

• Investors should closely monitor the delivery of 10Ah and 50Ah Goliath prototypes and subsequent customer validation results, as these are critical indicators of successful commercialization and potential revenue acceleration in 2026.
• Evaluate the progress of both Goliath (automotive/industrial) and Stereax (medtech) commercial sales, particularly the anticipated Stereax sales later this year, to gauge the effectiveness of Ilika's diversified technology strategy.
• While overall sales declined in 2025, focus on the growth of Goliath-specific revenue and the impact of new licensing agreements, as these represent future revenue streams from newly commercialized technologies.